2,5-DMA
2,5-dimethoxyamphetamine
Viewing r1.a1 — Oct 2, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
2,5-DMA (2,5-dimethoxyamphetamine) is a synthetic stimulant of the phenethylamine class. It is the unsubstituted parent compound of the DOx psychedelic series, distinguished by its near-total absence of perceptual effects. 2,5-DMA is a weak partial agonist at the serotonin 5-HT₂A receptor,[1] producing predominantly physical stimulation rather than the cortical disruption characteristic of psychedelic experience.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
DOI, DOB, DOM +4 moreDOI, DOB, DOM, DOC, LSD, psilocybin, mescaline show less
First synthesized in 1939 at Burroughs Wellcome Research Laboratories for evaluation as a sympathomimetic agent,[2] 2,5-DMA was later documented by Alexander Shulgin as PiHKAL entry #54 and scheduled internationally in 1985.[3] Its primary significance remains structural — as the scaffold from which potent psychedelics DOI, DOM, DOC, and DOB are derived.
Subjective effects include cardiovascular stimulation, tremor, wakefulness, and enhanced environmental interest. The experience is entirely somatic — a physical activation without visual, auditory, or cognitive alteration, closer to a moderate amphetamine dose than any classical psychedelic.[4] Nausea and sustained cardiovascular load are characteristic unsought effects.
2,5-DMA does not produce dependence or reinforcement,[5] and no lethal dose has been established in any species.[6] The primary risk is sympathomimetic — hypertension, tachycardia, and hyperthermia at high doses — compounded by the absence of controlled human data. No clinical trials, pharmacokinetic studies, or overdose case reports have been published; the current understanding rests on Shulgin's self-experiments and structural analogy to the DOx class.
History[edit]
Discovery
2,5-DMA was first synthesized in 1939 by Richard Baltzly and Johannes S. Buck at the Burroughs Wellcome Research Laboratories in New York, as part of a series of compounds evaluated for sympathomimetic (epinephrine-like) cardiovascular activity.[2] Alexander Shulgin later documented the compound as PiHKAL entry #54 in 1991, reporting self-experiments at 80 mg that revealed a profile dominated by physical effects — tremors, cardiovascular stimulation — with no sensory alterations.[4]
Scientific significance
Shulgin identified 2,5-DMA's importance not as a psychoactive substance in its own right but as the parent scaffold of the DOx series. Adding lipophilic groups at the 4-position of the ring transforms this perceptually inert stimulant into full psychedelics — DOM, DOB, DOI, and DOC — active at doses 20- to 80-fold lower.[7] The compound also found an unusual industrial application in Polaroid film manufacturing, creating anomalously large DEA production quotas for a Schedule I substance.[4][6]
Scheduling
The WHO Expert Committee on Drug Dependence reviewed 2,5-DMA at its 22nd meeting in 1985 and recommended placement under Schedule I of the 1971 Convention on Psychotropic Substances.[3] The committee characterized its pharmacology as similar to mescaline at low doses and amphetamine at high doses.[6] It remains Schedule I internationally and in the United States (DEA Drug Code 7396), with no accepted medical use and no modern research activity.
The name "DMA" follows standard phenethylamine abbreviation conventions — Di-Methoxy-Amphetamine — with the 2,5 prefix denoting methoxy positions on the aromatic ring. Among Shulgin's hundreds of documented compounds, 2,5-DMA is notable for what it lacks: despite being the structural ancestor of some of the most potent psychedelics ever synthesized, it produces no psychedelic effects whatsoever. Shulgin described it as "totally a physical trip" and noted its significance was as a chemical starting point rather than a destination.[4]
Chemistry[edit]
Structural class
2,5-DMA belongs to the substituted amphetamine subclass of the phenethylamine family. It consists of an amphetamine backbone with methoxy groups at the 2- and 5-positions of the aromatic ring. This 2,5-dimethoxy pattern defines the DOx pharmacophore — 2,5-DMA is the bare scaffold before any 4-position substituent is added.
The addition of lipophilic groups at the 4-position (methyl, bromo, iodo, chloro) transforms the compound from a weak stimulant into a potent psychedelic, increasing serotonin receptor affinity by orders of magnitude.[8] This structure-activity relationship — that the 2,5-dimethoxy pattern provides the pharmacophore while the 4-substituent determines potency — is one of the most well-characterized in psychedelic medicinal chemistry.
2,5-DMA is structurally related to mescaline (3,4,5-trimethoxyphenethylamine), differing in methoxy positions and the presence of an alpha-methyl group that defines the amphetamine series.
Molecular properties
| Molecular formula | C₁₁H₁₇NO₂ |
| Molecular weight | 195.26 g/mol |
Stereochemistry
2,5-DMA has one chirality center at the alpha-carbon, yielding R(−) and S(+) enantiomers. The R(−) form is expected to be more pharmacologically active based on data from DOx derivatives, where R(−)-enantiomers show greater potency at serotonin receptors.[9] All published human data and commercial material use the racemic mixture.
Physical properties
The hydrochloride salt melts at 114–116 °C.[4] No published data on solubility or stability under standard storage conditions exist. The free base is expected to be a liquid or low-melting solid, consistent with other low-molecular-weight substituted amphetamines.
Pharmacology[edit]
Mechanism of action
2,5-DMA acts primarily as a weak partial agonist at serotonin 5-HT₂A receptors.[1][9] Its binding affinity at this receptor is approximately 300-fold weaker than its 4-iodo derivative DOI,[1] directly explaining why 2,5-DMA produces physical stimulation without hallucinogenic effects.
Despite its amphetamine backbone, 2,5-DMA does not function as a monoamine releasing agent. Testing of compounds in this structural series found no significant activity at dopamine, serotonin, or norepinephrine transporters.[10] The 2,5-dimethoxy substitution pattern appears to abolish the monoamine releasing activity characteristic of unsubstituted amphetamine.
Trace amine-associated receptor 1 (TAAR1) represents a potential secondary target — related compounds in the same structural series show TAAR1 binding — but 2,5-DMA itself has not been specifically tested.[10]
The broader mechanism by which 5-HT₂A agonists produce psychedelic effects — triggering glutamate release in the prefrontal cortex and disrupting thalamocortical communication — has been characterized primarily through DOI.[5] Whether 2,5-DMA's weak partial agonism engages these cortical pathways at all remains unknown.
Pharmacokinetics
No pharmacokinetic data exist for 2,5-DMA in humans or animals. Half-life, bioavailability, and volume of distribution are entirely uncharacterized.
By structural analogy with the DOx class, the primary metabolic route involves O-demethylation at the 2- or 5-methoxy position, mediated by CYP2D6, followed by conjugation.[11] The duration of effects (6–8 hours oral)[4] provides the only indirect constraint on pharmacokinetic parameters.
DOx-class compounds weakly inhibit CYP2D6,[11] but at typical 2,5-DMA doses, plasma concentrations are unlikely to reach inhibitory thresholds, making clinically significant drug-metabolism interactions improbable.
Neuroscience[edit]
Where it acts
No neuroimaging or electrophysiological data have been published for 2,5-DMA specifically. By inference from the DOx class, the primary neural target is 5-HT₂A receptors on layer V pyramidal neurons in the prefrontal cortex, where activation triggers downstream glutamate release and disrupts cortical-subcortical communication.[5] Whether 2,5-DMA's weak binding achieves sufficient receptor occupancy to engage these cortical mechanisms — or whether its effects arise entirely through peripheral sympathomimetic pathways — remains an open question.
Theoretical significance
2,5-DMA occupies an informative position within current models of psychedelic action. Both the entropic brain hypothesis and the REBUS (Relaxed Beliefs Under Psychedelics) framework predict that 5-HT₂A agonism above a threshold occupancy produces increased neural entropy and relaxation of top-down predictive processing. 2,5-DMA's weak binding likely falls below this threshold, which may explain why it produces physical stimulation without perceptual or cognitive change. The compound thus serves as an implicit negative control: same pharmacophore, insufficient receptor engagement, absent psychedelic phenomenology.
Several unresolved questions surround 2,5-DMA's neural pharmacology. Does the compound achieve any meaningful 5-HT₂A occupancy in the brain at human-active doses, or are its effects entirely peripheral? Through what receptor or pathway does it produce sympathomimetic effects if it lacks monoamine transporter activity? Can it engage 5-HT₂A-dependent neuroplasticity pathways at achievable concentrations?
Subjective Effects[edit]
The experience of 2,5-DMA is one of physical activation without alteration of perception or cognition. Cardiovascular stimulation, muscle tension, tremor, and sustained wakefulness form the core, colored by an enhanced interest in surroundings that falls short of any psychedelic shift. Set and setting modulate the psychological tone of this stimulant state — pleasant engagement in comfortable environments, restlessness in uncomfortable ones — but do not produce perceptual phenomena at any documented dose.
Among the DOx series, 2,5-DMA occupies the pharmacological baseline. Its experience more closely resembles a moderate dose of amphetamine with pronounced peripheral sympathomimetic emphasis than any classical psychedelic, distinguishing it sharply from DOI and DOM, which produce full psychedelic experiences at doses 20- to 80-fold lower.
Effect Grid
The core 2,5-DMA experience. Cardiovascular stimulation becomes prominent — increased heart rate and blood pressure are clearly noticeable. Tremor, muscle tension, and sustained wakefulness define the physical profile. Shulgin described 80 mg as 'totally a physical trip' with 'nothing of a sensory nature.'
Cognitive effects are limited to enhanced interest in surroundings and mild cognitive euphoria. The experience is 'largely pleasant' but lacks any visual, auditory, or perceptual alterations. No psychedelic phenomenology occurs despite 2,5-DMA's structural relationship to the DOx series.
Duration is 6–8 hours. Appetite suppression and insomnia are likely. Temperature dysregulation and excessive sweating may occur.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual acuity enhancement · Auditory enhancement · Geometry · Sound sensitivity · Touch enhancement · Visual breathing · Visual processing acceleration · Tracers · Visual drifting · Visual haze / noise · Visual morphing
Touch enhancement · Visual breathing · Visual processing acceleration · Tracers · Visual drifting · Visual haze / noise · Visual morphing
Excessive sweating · Appetite suppression · Dry mouth · Body scan awareness · Muscle tension · Heart rate perception changes · Insomnia · Vasoconstriction · Spontaneous body sensations · Body high · Dehydration sensation · Physical fatigue · Respiratory stimulation · Restlessness · Bodily lightness · Breathing alteration · Bruxism · Headache · Laughter fits · Nausea · Sexual arousal enhancement · Tingling / electric sensations · Motor control enhancement · Dizziness · Tactile euphoria · Trembling · Vibrations / buzzing · Vomiting
Body scan awareness · Muscle tension · Heart rate perception changes · Insomnia · Spontaneous body sensations · Body high · Dehydration sensation · Physical fatigue · Respiratory stimulation · Restlessness · Bodily lightness · Breathing alteration · Bruxism · Headache · Laughter fits · Nausea · Sexual arousal enhancement · Tingling / electric sensations · Motor control enhancement · Dizziness · Tactile euphoria · Trembling · Vibrations / buzzing · Vomiting
Novelty enhancement · Aesthetic enhancement · Cognitive fatigue · Focus enhancement · Openness enhancement · Humor enhancement · Analysis enhancement · Creativity enhancement · Information processing enhancement · Thought connectivity · Pattern recognition enhancement · Cognitive flexibility · Conceptual thinking · Immersion enhancement · Introspection enhancement · Multiple thought streams · Language enhancement · Memory enhancement · Thought organization · Cognitive impairment · Confusion · Decision impairment · Increased nature relatedness · Thought disorganization · Thought loops
Focus enhancement · Openness enhancement · Humor enhancement · Analysis enhancement · Creativity enhancement · Information processing enhancement · Thought connectivity · Pattern recognition enhancement · Cognitive flexibility · Conceptual thinking · Immersion enhancement · Introspection enhancement · Multiple thought streams · Language enhancement · Memory enhancement · Thought organization · Cognitive impairment · Confusion · Increased nature relatedness · Thought disorganization · Thought loops
Emotional lability · Empathy enhancement · Irritability · Anhedonia · Catharsis · Simultaneous emotions · Dysphoria · Mania
Anhedonia · Catharsis · Simultaneous emotions · Dysphoria
Disinhibition · Social connection · Trust enhancement · Flow state · Ego inflation · Craving · Derealization · Depersonalization · Cognitive disconnection
Ego inflation · Craving · Derealization · Depersonalization · Cognitive disconnection
Timeline
Gradual physical activation becomes noticeable — mild cardiovascular awareness, slight increase in heart rate, emerging wakefulness. Effects are subtle and primarily somatic.
Sympathomimetic stimulation plateau — pronounced cardiovascular activation, tremor, muscle tension, sustained wakefulness, and enhanced environmental interest. No perceptual or visual changes. Shulgin described this phase as 'totally a physical trip.
Gradual diminution of stimulant effects — cardiovascular activation subsides, muscle tension eases, wakefulness persists at reduced intensity.
⚠ Do not drive or operate machinery until all residual stimulation and cardiovascular effects have fully resolved.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 8.5 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- DOI · DOB · DOM
Toxicity
No lethal dose has been established for 2,5-DMA in any species. No human overdose case reports or fatalities have been published.[6] The toxic dose in humans is unknown.safety citation needed
Sympathomimetic risk
The primary toxicological concern is sympathomimetic overload: elevated heart rate, high blood pressure, elevated body temperature, and agitation. These effects are documented at active doses and would be expected to intensify with dose escalation.[4]
Severe poisoning with the structurally related NBOMe compounds has produced rapid heart rate (90% of cases), high blood pressure (70%), agitation (60%), and seizures.[12] While 2,5-DMA is pharmacologically much weaker, it shares the sympathomimetic component of this toxicity profile.inferred
No organ-specific toxicity (liver, kidney, neurological) has been documented. Cardiovascular strain from sympathomimetic activation represents the most plausible acute risk at high doses.
Psychological risks
Shulgin's reports indicate minimal psychological effects — specifically, the absence of perceptual disturbances or psychedelic-type distress at doses up to 80 mg.[4] No reports of anxiety, panic, psychosis, or HPPD have been published.
At high doses, the stimulant profile raises the possibility of dose-dependent anxiety, restlessness, and paranoia — effects common to sympathomimetic agents. The WHO ECDD noted that higher doses produce amphetamine-like effects,[6] which may include stimulant-associated agitation.
Tolerance and dependence
2,5-DMA does not produce dependence. Phenylalkylamine serotonin 2A receptor agonists do not generate reinforcing or rewarding effects associated with addictive substances.[5] No evidence of physical dependence, withdrawal, or compulsive use has been reported.
Cross-tolerance with classical psychedelics is expected based on the shared 5-HT₂A mechanism. Repeated administration of DOI produces rapid tolerance via downregulation in the frontal cortex,[13] and cross-tolerance between phenethylamine psychedelics is insurmountable through dose escalation.[14]
The degree to which tolerance develops to 2,5-DMA's predominant stimulant effects — which may not be primarily 5-HT₂A-mediated — has not been studied.inferred
Drug interactions
The primary interaction risk arises from 2,5-DMA's serotonergic mechanism. Combination with monoamine oxidase inhibitors (MAOIs) is potentially dangerous through both serotonergic potentiation and inhibition of 2,5-DMA's oxidative metabolism.inferred
The tramadol combination carries risk of serotonin syndrome due to tramadol's serotonin-norepinephrine reuptake inhibitor combined with 2,5-DMA's 5-HT₂A agonism.safety citation needed
Combination with SSRIs or SNRIs carries theoretical serotonin syndrome risk through additive serotonergic stimulation.inferred
CYP2D6-mediated interactions are theoretically possible but unlikely at typical doses — plasma concentrations would not reach inhibitory thresholds.[11]
Contraindications
No substance-specific contraindication data exist. The following are inferred from the sympathomimetic profileinferred:
Cardiovascular conditions: Pre-existing high blood pressure, heart rhythm disorders, coronary artery disease, and structural heart disease are contraindicated given documented cardiovascular stimulation.[4]
Seizure disorders: Sympathomimetic compounds may lower seizure threshold.inferred
Concurrent serotonergic medication: MAOIs, SSRIs, SNRIs, and tramadol are contraindicated due to serotonin syndrome risk.
Pregnancy and lactation: No reproductive safety data exist. Use is contraindicated.inferred
Harm Reduction[edit]
Forms & Identification
2,5-DMA is exceptionally rare on contemporary markets. Any material encountered is likely of research-chemical origin with no quality assurance. Given the compound's high active dose (80–160 mg), it cannot fit on standard blotter paper — if sold as blotter, it is almost certainly mislabeled or a different, more potent substance.
Reagent testing can confirm the presence of a methoxylated amphetamine but cannot distinguish 2,5-DMA from its far more potent 4-substituted derivatives (DOI, DOB, DOC, DOM). Quantitative analysis (GC-MS or comparable) is the only reliable identification method. Treat unverified material with extreme caution — confusion with DOx compounds active at 1–5 mg could produce a dangerous overdose if dosed at 2,5-DMA levels.
Guidelines
- Test all material with reagent kits AND quantitative analysis where possible — reagents alone cannot distinguish 2,5-DMA from far more potent DOx compounds
- Weigh doses with a milligram-precision scale; volumetric dosing is acceptable for solutions
- Start at the low end of the active range and wait at least 2 hours before considering redosing
- Monitor heart rate; if resting heart rate exceeds 120 bpm or chest discomfort develops, do not redose
- Ensure adequate hydration throughout the experience
- Avoid physical exertion that compounds cardiovascular strain
- Do not combine with other stimulants, serotonergic substances, or MAOIs
Set & Setting
The experience is predominantly physical — cardiovascular stimulation and wakefulness without perceptual change. A calm, comfortable environment reduces the likelihood of stimulant-associated anxiety. The 6–8 hour duration means planning for a full day without obligations.
No psychological preparation for psychedelic-type experiences is necessary, as the compound does not produce them. A sitter is less critical than with psychedelics but remains advisable given the unknown toxicity profile and sympathomimetic load.
Aftercare & integration. The comedown from 2,5-DMA resembles that of other stimulants — fatigue, mild low mood, and difficulty sleeping may follow. Prioritize sleep recovery: a dark, quiet environment and avoidance of additional stimulants (including caffeine) in the 12 hours following the experience.
Nutrition and hydration support recovery. Light meals during and after the experience help offset the appetite suppression common to sympathomimetic compounds. No psychological integration in the psychedelic sense is typically needed, as the experience does not produce meaningful perceptual or cognitive alteration.
Recovery & Support
2,5-DMA does not produce physical dependence or withdrawal. Compulsive use patterns have not been documented for this compound. If stimulant use of any kind has become problematic, general stimulant recovery resources apply — including SMART Recovery, local addiction services, and peer support communities. Seek professional support if use of stimulants is interfering with daily functioning, relationships, or health.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Chest pain or pressure
- Heart rate above 150 bpm or irregular heartbeat
- Severe headache with visual disturbance (possible blood pressure crisis)
- Body temperature high enough to feel through clothing
- Seizure or loss of consciousness
- Severe agitation unresponsive to reassurance
Immediate steps:
- Call emergency services if any of the above are present
- Move the person to a cool, quiet environment
- Remove excess clothing if body temperature is elevated
- Do not induce vomiting
- If unconscious but breathing, place in the recovery position
- Monitor breathing and pulse until help arrives
What to tell the dispatcher:
Name the substance (2,5-DMA or dimethoxyamphetamine), approximate amount taken, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from drug-related prosecution.
No specific reversal agent exists for sympathomimetic toxicity. Hospital treatment is supportive: cooling, blood pressure management, and sedation with benzodiazepines if needed.
Legal Status[edit]
2,5-DMA is internationally controlled as a Schedule I substance under the 1971 United Nations Convention on Psychotropic Substances, following the recommendation of the WHO Expert Committee on Drug Dependence in 1985.[3] Most jurisdictions classify it under broad amphetamine or phenethylamine scheduling provisions rather than substance-specific legislation.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | DEA Drug Code 7396; no accepted medical use[15] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled under generic amphetamine/phenethylamine provision[15] |
| Canada | Schedule I (CDSA) | Controlled Drugs and Substances Act[15] |
| Australia | Controlled (narcotic) | Listed on Office of Drug Control register[16] |
| Germany | Controlled (NpSG) | Neue-psychoaktive-Stoffe-Gesetz since November 2016; possession not punishable but production and distribution are[16] |
| International | Schedule I (1971 Convention) | Recommended by WHO ECDD at 22nd meeting (1985)[3] |
The specific year 2,5-DMA was initially placed on Schedule I in the United States has not been confirmed; the compound may have been included under the broad amphetamine provisions of the Controlled Substances Act of 1970.citation needed
references
- [1] ^abcHemanth P, Nistala P, Nguyen VT, Eltit JM, Glennon RA, Dukat M (2023) Binding and functional structure-activity similarities of 4-substituted 2,5-dimethoxyphenyl isopropylamine analogues at 5-HT2A and 5-HT2B serotonin receptors. — Frontiers in Pharmacology doi:10.3389/fphar.2023.1101290
- [2]
- [3]
- [4]
- [5] ^abcdHalberstadt AL, Geyer MA (2011) Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens — Neuropharmacology doi:10.1016/j.neuropharm.2011.01.017
- [6]